Literature DB >> 34313782

Antipsychotics Effects on Network-Level Reconfiguration of Cortical Morphometry in First-Episode Schizophrenia.

Yuchao Jiang1,2, Yingchan Wang3, Huan Huang1,2, Hui He1, Yingying Tang3, Wenjun Su3, Lihua Xu3, Yanyan Wei3, Tianhong Zhang3, Hao Hu3, Jinhong Wang3, Dezhong Yao1,4, Jijun Wang3,5,6, Cheng Luo1,2,4.   

Abstract

Cortical thickness reductions are evident in schizophrenia (SZ). Associations between antipsychotic medications (APMs) and cortical morphometry have been explored in SZ patients. This raises the question of whether the reconfiguration of morphological architecture by APM plays potential compensatory roles for abnormalities in the cerebral cortex. Structural magnetic resonance imaging was obtained from 127 medication-naive first-episode SZ patients and 133 matched healthy controls. Patients received 12 weeks of APM and were categorized as responders (n = 75) or nonresponders (NRs, n = 52) at follow-up. Using surface-based morphometry and structural covariance (SC) analysis, this study investigated the short-term effects of antipsychotics on cortical thickness and cortico-cortical covariance. Global efficiency was computed to characterize network integration of the large-scale structural connectome. The relationship between covariance and cortical thinning was examined by SC analysis among the top-n regions with thickness reduction. Widespread cortical thickness reductions were observed in pre-APM patients. Post-APM patients showed more reductions in cortical thickness, even in the frontotemporal regions without baseline reductions. Covariance analysis revealed strong cortico-cortical covariance and higher network integration in responders than in NRs. For the NRs, some of the prefrontal and temporal nodes were not covariant between the top-n regions with cortical thickness reduction. Antipsychotic effects are not restricted to a single brain region but rather exhibit a network-level covariance pattern. Neuroimaging connectomics highlights the positive effects of antipsychotics on the reconfiguration of brain architecture, suggesting that abnormalities in regional morphology may be compensated by increasing interregional covariance when symptoms are controlled by antipsychotics.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antipsychotics; brain connectivity; cortical thickness; first-episode schizophrenia; magnetic resonance imaging; structural covariance network; treatment response

Mesh:

Substances:

Year:  2022        PMID: 34313782      PMCID: PMC8781340          DOI: 10.1093/schbul/sbab082

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   7.348


  38 in total

1.  Neural markers of early remission in first-episode schizophrenia: a volumetric neuroimaging study of the parahippocampus.

Authors:  Michael Bodnar; Ashok K Malla; Ridha Joober; Catherine Lord; Evelyne Smith; Jens Pruessner; Martin Lepage
Journal:  Psychiatry Res       Date:  2012-01-27       Impact factor: 3.222

2.  Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys.

Authors:  Glenn T Konopaske; Karl-Anton Dorph-Petersen; Joseph N Pierri; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2006-10-25       Impact factor: 7.853

3.  Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).

Authors:  Han Boter; Joseph Peuskens; Jan Libiger; W Wolfgang Fleischhacker; Michael Davidson; Silvana Galderisi; René S Kahn
Journal:  Schizophr Res       Date:  2009-10-09       Impact factor: 4.939

Review 4.  Mass univariate analysis of event-related brain potentials/fields I: a critical tutorial review.

Authors:  David M Groppe; Thomas P Urbach; Marta Kutas
Journal:  Psychophysiology       Date:  2011-09-06       Impact factor: 4.016

5.  Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

Authors:  George Bartzokis; Po H Lu; Erika P Raven; Chetan P Amar; Nicole R Detore; Alexander J Couvrette; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2012-07-17       Impact factor: 4.939

Review 6.  Neurodevelopmental model of schizophrenia: update 2012.

Authors:  J L Rapoport; J N Giedd; N Gogtay
Journal:  Mol Psychiatry       Date:  2012-04-10       Impact factor: 15.992

7.  Structural Covariance Reveals Alterations in Control and Salience Network Integrity in Chronic Schizophrenia.

Authors:  R Nathan Spreng; Elizabeth DuPre; Jie Lisa Ji; Genevieve Yang; Caroline Diehl; John D Murray; Godfrey D Pearlson; Alan Anticevic
Journal:  Cereb Cortex       Date:  2019-12-17       Impact factor: 5.357

8.  Structural covariance in the hallucinating brain: a voxel-based morphometry study.

Authors:  Gemma Modinos; Ans Vercammen; Andrea Mechelli; Henderikus Knegtering; Philip K McGuire; André Aleman
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

9.  Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia.

Authors:  André Zugman; Ary Gadelha; Idaiane Assunção; João Sato; Vanessa K Ota; Deyvis L Rocha; Jair J Mari; Sintia I Belangero; Rodrigo A Bressan; Elisa Brietzke; Andrea P Jackowski
Journal:  Schizophr Res       Date:  2013-05-28       Impact factor: 4.939

10.  Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrification.

Authors:  Lena Palaniyappan; Tiago Reis Marques; Heather Taylor; Valeria Mondelli; A A T Simone Reinders; Stefania Bonaccorso; Annalisa Giordano; Marta DiForti; Andrew Simmons; Anthony S David; Carmine M Pariante; Robin M Murray; Paola Dazzan
Journal:  Schizophr Bull       Date:  2016-06-28       Impact factor: 7.348

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.